Moderna vaccine cuts skin cancer risk

Moderna and Merck’s mRNA cancer vaccine delivered positive results in a late-stage melanoma trial, bringing it one step closer to potentially becoming available as early as next year, pending regulatory approval. LiveNOW’s Austin Westfall spoke about the cancer breakthrough with Dr. Douglas Johnson, Clinical Director of Melanoma at the Vanderbilt-Ingram Cancer Center.